Bio-Techne and Refeyn close critical gap in bispecific antibody and biosimilar characterization.

{
  "signal_id": "6039c55b-580a-4ffc-a9fe-3b6ea73b407c",
  "signal_type": "news",
  "signal_subtype": "integrates_with",
  "detected_at": "2026-06-04T00:00:00+00:00",
  "company": {
    "name": "Bio-Techne",
    "domain": "bio-techne.com"
  },
  "data": {
    "url": "https://investors.bio-techne.com/press-releases/detail/534/biotechne-and-refeyn-close-critical-gap-in-bispecific",
    "title": "Bio-Techne and Refeyn close critical gap in bispecific antibody and biosimilar characterization.",
    "excerpt": "Bio-Techne and Refeyn close critical gap in bispecific antibody and biosimilar characterization.\n\n* New integrated workflow combines icIEF fractionation and mass photometry\n* Enables direct characterization of aggregation and size within icIEF-resolved charge variants\n* Four-hour workflow reduces development risk and accelerates biosimilar manufacturing\n\nMINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first-of-its-kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.\n\nBy combining R&D Systems MauriceFlex(TM) imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn's TwoMP mass photometry platform, researchers can directly correlate charge heterogeneity with molecular weight and aggregation at single-molecule resolution in a streamlined four-hour workflow.\n\nBispecific antibodies are among the fastest-growing classes of biotherapeutics, but their structural complexity makes thorough characterization challenging. Incomplete characterization can delay development, increase manufacturing risk, and lead to costly late-stage failures.\n\nThe MauriceFlex(TM) system delivers high-resolution separation and...",
    "summary": "Bio-Techne integrated with Refeyn Ltd. on Jun 4th '26.",
    "category": "integrates_with",
    "found_at": "2026-06-04T00:00:00Z",
    "location": "Minneapolis, Minnesota, United States, Northern America, Americas",
    "planning": false,
    "image_url": "https://resources.bio-techne.com/images/Social/2019-bio-techne-logo.png",
    "confidence": 0.2088,
    "published_at": "2026-06-04T00:00:00Z",
    "location_data": [
      {
        "city": "Minneapolis",
        "state": "Minnesota",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-06-04",
    "article_sentence": "MINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first-of-its-kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars."
  }
}

curl https://signals.autobound.ai/v1/signals/6039c55b-580a-4ffc-a9fe-3b6ea73b407c \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bio-techne.com","limit":20}'